{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T23:29:10Z","timestamp":1783121350129,"version":"3.54.6"},"reference-count":89,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,31]],"date-time":"2025-01-31T00:00:00Z","timestamp":1738281600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["23dk0207061"],"award-info":[{"award-number":["23dk0207061"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["24dk0207073"],"award-info":[{"award-number":["24dk0207073"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP19jm0210058"],"award-info":[{"award-number":["JP19jm0210058"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["21dk0207046"],"award-info":[{"award-number":["21dk0207046"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","neurotherapeuticsjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neurotherapeutics"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1016\/j.neurot.2025.e00548","type":"journal-article","created":{"date-parts":[[2025,2,11]],"date-time":"2025-02-11T17:42:37Z","timestamp":1739295757000},"page":"e00548","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Proteolytic therapeutic modalities for amyloidoses: Insights into immunotherapy, PROTAC, and photo-oxygenation"],"prefix":"10.1016","volume":"22","author":[{"given":"Mai","family":"Kuriyama","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chu Fan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsuya","family":"Nagase","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youhei","family":"Sohma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Motomu","family":"Kanai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukiko","family":"Hori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taisuke","family":"Tomita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.neurot.2025.e00548_bib1","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.jalz.2011.03.003","article-title":"Toward defining the preclinical stages of Alzheimer\u2019s disease: recommendations from the National Institute on Aging-Alzheimer\u2019s Association workgroups on diagnostic guidelines for Alzheimer\u2019s disease","volume":"7","author":"Sperling","year":"2011","journal-title":"Am J Alzheimers Dis Other Demen"},{"issue":"8","key":"10.1016\/j.neurot.2025.e00548_bib2","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1038\/78682","article-title":"Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease","volume":"6","author":"Bard","year":"2000","journal-title":"Nat Med"},{"issue":"7","key":"10.1016\/j.neurot.2025.e00548_bib3","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1093\/brain\/awz142","article-title":"Persistent neuropathological effects 14 years following amyloid-\u03b2 immunization in Alzheimer\u2019s disease","volume":"142","author":"Nicoll","year":"2019","journal-title":"Brain"},{"issue":"7618","key":"10.1016\/j.neurot.2025.e00548_bib4","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1038\/nature19323","article-title":"The antibody aducanumab reduces A\u03b2 plaques in Alzheimer\u2019s disease","volume":"537","author":"Sevigny","year":"2016","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.neurot.2025.e00548_bib5","doi-asserted-by":"crossref","first-page":"197","DOI":"10.14283\/jpad.2022.30","article-title":"Two randomized phase 3 studies of aducanumab in early Alzheimer\u2019s disease","volume":"9","author":"Budd","year":"2022","journal-title":"J\u00a0Prev Alzheimers Dis"},{"issue":"1","key":"10.1016\/j.neurot.2025.e00548_bib6","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1056\/NEJMoa2212948","article-title":"Lecanemab in early Alzheimer\u2019s disease","volume":"388","author":"van Dyck","year":"2023","journal-title":"N\u00a0Engl J Med"},{"issue":"18","key":"10.1016\/j.neurot.2025.e00548_bib7","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1056\/NEJMoa2100708","article-title":"Donanemab in early Alzheimer\u2019s disease","volume":"384","author":"Mintun","year":"2021","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"10.1016\/j.neurot.2025.e00548_bib8","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/s41573-021-00371-6","article-title":"PROTAC targeted protein degraders: the past is prologue","volume":"21","author":"B\u00e9k\u00e9s","year":"2022","journal-title":"Nat Rev Drug Discov"},{"issue":"32","key":"10.1016\/j.neurot.2025.e00548_bib9","doi-asserted-by":"crossref","first-page":"2447","DOI":"10.1080\/14796694.2024.2377530","article-title":"VERITAC-2: a Phase III study of vepdegestrant, a PROTAC ER degrader, versus fulvestrant in ER+\/HER2- advanced breast cancer","volume":"20","author":"Hamilton","year":"2024","journal-title":"Future Oncol"},{"issue":"5","key":"10.1016\/j.neurot.2025.e00548_bib10","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1002\/anie.201308001","article-title":"Attenuation of the aggregation and neurotoxicity of amyloid-\u03b2 peptides by catalytic photooxygenation","volume":"53","author":"Taniguchi","year":"2014","journal-title":"Angew Chem Int Ed"},{"issue":"10","key":"10.1016\/j.neurot.2025.e00548_bib11","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1038\/nchem.2550","article-title":"Switchable photooxygenation\u00a0catalysts that sense higher-order amyloid structures","volume":"8","author":"Taniguchi","year":"2016","journal-title":"Nat Chem"},{"issue":"44","key":"10.1016\/j.neurot.2025.e00548_bib12","doi-asserted-by":"crossref","first-page":"6165","DOI":"10.1039\/C9CC01728C","article-title":"Photo-oxygenation inhibits tau amyloid formation","volume":"55","author":"Suzuki","year":"2019","journal-title":"Chem Commun"},{"issue":"6","key":"10.1016\/j.neurot.2025.e00548_bib13","doi-asserted-by":"crossref","first-page":"1884","DOI":"10.1093\/brain\/awab058","article-title":"Photo-oxygenation by a biocompatible catalyst reduces amyloid-\u03b2 levels in Alzheimer\u2019s disease mice","volume":"144","author":"Ozawa","year":"2021","journal-title":"Brain"},{"issue":"12","key":"10.1016\/j.neurot.2025.e00548_bib14","doi-asserted-by":"crossref","DOI":"10.1096\/fj.202301533R","article-title":"Photo-oxygenation of histidine residue inhibits \u03b1-synuclein aggregation","volume":"37","author":"Nakamura","year":"2023","journal-title":"FASEB J"},{"issue":"38","key":"10.1016\/j.neurot.2025.e00548_bib15","doi-asserted-by":"crossref","first-page":"5745","DOI":"10.1039\/D3CC00665D","article-title":"Attenuation of \u03b1-synuclein aggregation by catalytic photo-oxygenation","volume":"59","author":"Iwai","year":"2023","journal-title":"Chem Commun"},{"issue":"11","key":"10.1016\/j.neurot.2025.e00548_bib16","doi-asserted-by":"crossref","DOI":"10.1002\/tcr.202300198","article-title":"Histidine photooxygenation chemistry:\u00a0mechanistic evidence and elucidation","volume":"23","author":"Matsukawa","year":"2023","journal-title":"Chem Rec"},{"issue":"13","key":"10.1016\/j.neurot.2025.e00548_bib17","doi-asserted-by":"crossref","first-page":"9750","DOI":"10.1126\/sciadv.abc9750","article-title":"Catalytic\u00a0photooxygenation degrades brain A\u03b2 in vivo","volume":"7","author":"Nagashima","year":"2021","journal-title":"Sci Adv"},{"issue":"15","key":"10.1016\/j.neurot.2025.e00548_bib18","doi-asserted-by":"crossref","first-page":"2710","DOI":"10.1021\/acschemneuro.3c00264","article-title":"Quantitative assays for catalytic photo-oxygenation of alzheimer disease-related tau proteins","volume":"14","author":"Umeda","year":"2023","journal-title":"ACS Chem Neurosci"},{"issue":"26","key":"10.1016\/j.neurot.2025.e00548_bib19","doi-asserted-by":"crossref","DOI":"10.1002\/advs.202401346","article-title":"Leuco ethyl violet as self-activating prodrug photocatalyst for in vivo amyloid-selective oxygenation","volume":"11","author":"Furuta","year":"2024","journal-title":"Adv Sci"},{"issue":"8","key":"10.1016\/j.neurot.2025.e00548_bib20","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1055\/a-2182-7614","article-title":"Rose bengal promoted catalytic amyloid-\u03b2 oxygenation by sonoactivation","volume":"35","author":"Atsumi","year":"2024","journal-title":"Synlett"},{"issue":"4","key":"10.1016\/j.neurot.2025.e00548_bib21","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1016\/j.chempr.2018.02.008","article-title":"Near-infrared photoactivatable oxygenation catalysts of amyloid peptide","volume":"4","author":"Ni","year":"2018","journal-title":"Chem"},{"issue":"31","key":"10.1016\/j.neurot.2025.e00548_bib22","doi-asserted-by":"crossref","DOI":"10.1002\/anie.202405605","article-title":"Unimolecular chemiexcited oxygenation of pathogenic amyloids","volume":"63","author":"Umeda","year":"2024","journal-title":"Angew Chem Int Ed"},{"issue":"6740","key":"10.1016\/j.neurot.2025.e00548_bib23","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1038\/22124","article-title":"Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse","volume":"400","author":"Schenk","year":"1999","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.neurot.2025.e00548_bib24","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1212\/01.WNL.0000073623.84147.A8","article-title":"Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization","volume":"61","author":"Orgogozo","year":"2003","journal-title":"Neurology"},{"issue":"4","key":"10.1016\/j.neurot.2025.e00548_bib25","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1056\/NEJMoa1304839","article-title":"Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer\u2019s disease","volume":"370","author":"Salloway","year":"2014","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"10.1016\/j.neurot.2025.e00548_bib26","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1056\/NEJMoa1705971","article-title":"Trial of solanezumab for mild dementia due to Alzheimer\u2019s disease","volume":"378","author":"Honig","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.neurot.2025.e00548_bib27","doi-asserted-by":"crossref","first-page":"6412","DOI":"10.1038\/s41598-018-24501-0","article-title":"Structural and kinetic basis for the selectivity of aducanumab for aggregated forms of amyloid-\u03b2","volume":"8","author":"Arndt","year":"2018","journal-title":"Sci Rep"},{"issue":"15","key":"10.1016\/j.neurot.2025.e00548_bib28","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1212\/WNL.0000000000200176","article-title":"Aducanumab use in symptomatic Alzheimer disease evidence in focus","volume":"98","author":"Day","year":"2022","journal-title":"Neurology"},{"issue":"9","key":"10.1016\/j.neurot.2025.e00548_bib29","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1056\/NEJMp2111320","article-title":"Controversy and progress in Alzheimer\u2019s disease - FDA approval of aducanumab","volume":"385","author":"Rabinovici","year":"2021","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"10.1016\/j.neurot.2025.e00548_bib30","doi-asserted-by":"crossref","first-page":"575","DOI":"10.3233\/JAD-140741","article-title":"The murine version of BAN2401 (mAb158) selectively reduces amyloid-\u03b2 protofibrils in brain and cerebrospinal fluid of tg-ArcSwe mice","volume":"43","author":"Tucker","year":"2015","journal-title":"J\u00a0Alzheimers Dis"},{"issue":"6","key":"10.1016\/j.neurot.2025.e00548_bib31","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1001\/jama.2023.13239","article-title":"Donanemab in early symptomatic Alzheimer disease: the TRAILBLAZER-ALZ 2 randomized clinical trial","volume":"330","author":"Sims","year":"2023","journal-title":"JAMA"},{"issue":"45","key":"10.1016\/j.neurot.2025.e00548_bib32","doi-asserted-by":"crossref","first-page":"38825","DOI":"10.1074\/jbc.R111.288308","article-title":"Pyroglutamate amyloid-\u03b2 (A\u03b2): a hatchet man in Alzheimer disease","volume":"286","author":"Jawhar","year":"2011","journal-title":"J\u00a0Biol Chem"},{"issue":"11","key":"10.1016\/j.neurot.2025.e00548_bib33","doi-asserted-by":"crossref","first-page":"4414","DOI":"10.1093\/brain\/awad188","article-title":"Amyloid-related imaging abnormalities (ARIA): radiological, biological and clinical characteristics","volume":"146","author":"Hampel","year":"2023","journal-title":"Brain"},{"issue":"6248","key":"10.1016\/j.neurot.2025.e00548_bib34","doi-asserted-by":"crossref","DOI":"10.1126\/science.1255555","article-title":"Alzheimer\u2019s and Parkinson\u2019s diseases: the prion concept in relation to assembled A\u03b2, tau, and \u03b1-synuclein","volume":"349","author":"Goedert","year":"2015","journal-title":"Science"},{"key":"10.1016\/j.neurot.2025.e00548_bib35","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1146\/annurev-neuro-071714-033828","article-title":"Neurodegenerative diseases: expanding the prion concept","volume":"38","author":"Walker","year":"2015","journal-title":"Annu Rev Neurosci"},{"issue":"39","key":"10.1016\/j.neurot.2025.e00548_bib36","doi-asserted-by":"crossref","first-page":"13454","DOI":"10.1523\/JNEUROSCI.1292-12.2012","article-title":"Antibody-aided clearance of extracellular \u03b1-synuclein prevents cell-to-cell aggregate transmission","volume":"32","author":"Bae","year":"2012","journal-title":"J\u00a0Neurosci"},{"issue":"1","key":"10.1016\/j.neurot.2025.e00548_bib37","doi-asserted-by":"crossref","first-page":"4658","DOI":"10.1038\/s41598-019-41105-4","article-title":"Antibody-mediated clearance of tau in primary mouse microglial cultures requires Fc\u03b3-receptor binding and functional lysosomes","volume":"9","author":"Andersson","year":"2019","journal-title":"Sci Rep"},{"issue":"2","key":"10.1016\/j.neurot.2025.e00548_bib38","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1074\/jbc.M114.589309","article-title":"Conformation determines the seeding potencies of native and recombinant Tau aggregates","volume":"290","author":"Falcon","year":"2015","journal-title":"J\u00a0Biol Chem"},{"issue":"10","key":"10.1016\/j.neurot.2025.e00548_bib39","doi-asserted-by":"crossref","first-page":"5129","DOI":"10.1073\/pnas.97.10.5129","article-title":"Assembly of tau protein into Alzheimer paired helical filaments depends on a local sequence motif ((306)VQIVYK(311)) forming beta structure","volume":"97","author":"Von Bergen","year":"2000","journal-title":"Proc Natl Acad Sci USA"},{"issue":"44","key":"10.1016\/j.neurot.2025.e00548_bib40","article-title":"First-in-man tau vaccine targeting structural determinants essential for pathological tau-tau interaction reduces tau oligomerisation and neurofibrillary degeneration in an Alzheimer\u2019s disease model","volume":"6","author":"Kontsekova","year":"2014","journal-title":"Alzheimer\u2019s Res Ther"},{"issue":"6","key":"10.1016\/j.neurot.2025.e00548_bib41","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1038\/s43587-021-00070-2","article-title":"ADAMANT: a placebo-controlled randomized phase 2 study of AADvac1, an active immunotherapy against pathological tau in Alzheimer\u2019s disease","volume":"1","author":"Novak","year":"2021","journal-title":"Nat Aging"},{"key":"10.1016\/j.neurot.2025.e00548_bib42","unstructured":"Eisai presents latest clinical findings suggesting inhibition of tau propagation by anti-MTBR tau antibody E2814 at the 17th clinical trials on Alzheimer\u2019s disease conference (CTAD) [press release]. Tokyo: Eisai Co., Ltd. Available from: https:\/\/www.eisai.com\/news\/2024\/pdf\/enews202480pdf.pdf. Accessed 21 November 2024."},{"issue":"6","key":"10.1016\/j.neurot.2025.e00548_bib43","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1007\/s00401-014-1256-4","article-title":"Next-generation active immunization approach for synucleinopathies - implications for Parkinson\u2019s Disease clinical trials","volume":"127","author":"Mandler","year":"2014","journal-title":"Acta Neuropathol"},{"issue":"1","key":"10.1016\/j.neurot.2025.e00548_bib44","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/s00401-021-02381-5","article-title":"Immunisation with UB-312 in the Thy1SNCA mouse prevents motor performance deficits and oligomeric \u03b1-synuclein accumulation in the brain and gut","volume":"143","author":"Nimmo","year":"2021","journal-title":"Acta Neuropathol"},{"issue":"4","key":"10.1016\/j.neurot.2025.e00548_bib45","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0019338","article-title":"Passive\u00a0immunization reduces behavioral and neuropathological deficits in an alpha-synuclein transgenic model of lewy body disease","volume":"6","author":"Masliah","year":"2011","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.neurot.2025.e00548_bib46","doi-asserted-by":"crossref","DOI":"10.1080\/19420862.2021.1994690","article-title":"Nonclinical safety evaluation, pharmacokinetics, and target engagement of Lu AF82422, a monoclonal IgG1 antibody against alpha-synuclein in development for treatment of synucleinopathies","volume":"13","author":"Fjord-Larsen","year":"2021","journal-title":"mAbs"},{"key":"10.1016\/j.neurot.2025.e00548_bib47","doi-asserted-by":"crossref","DOI":"10.1016\/j.nbd.2019.104582","article-title":"Preclinical development of a high affinity \u03b1-synuclein antibody, MEDI1341, that can enter the brain, sequester extracellular \u03b1-synuclein and attenuate \u03b1-synuclein spreading in vivo","volume":"132","author":"Schofield","year":"2019","journal-title":"Neurobiol Dis"},{"key":"10.1016\/j.neurot.2025.e00548_bib48","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s13024-015-0008-9","article-title":"Active immunization against alpha-synuclein ameliorates the degenerative pathology and prevents demyelination in a model of multiple system atrophy","volume":"10","author":"Mandler","year":"2015","journal-title":"Mol Neurodegener"},{"issue":"10","key":"10.1016\/j.neurot.2025.e00548_bib49","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1001\/jamaneurol.2018.1487","article-title":"Safety and tolerability of multiple ascending doses of PRX002\/RG7935, an anti\u2013\u03b1-synuclein monoclonal antibody, in patients with Parkinson disease: a randomized clinical trial","volume":"75","author":"Jankovic","year":"2018","journal-title":"JAMA Neurol"},{"issue":"6","key":"10.1016\/j.neurot.2025.e00548_bib50","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1002\/mds.29784","article-title":"Randomized phase I trial of the \u03b1-synuclein antibody Lu AF82422","volume":"39","author":"Buur","year":"2024","journal-title":"Mov Disord"},{"issue":"17_suppl ment_2","key":"10.1016\/j.neurot.2025.e00548_bib51","article-title":"Reducing \u03b1-synuclein in human CSF; an evaluation of safety, tolerability, pharmacokinetics and pharmacodynamics of MEDI1341, an \u03b1-Synuclein-specific antibody, in healthy volunteers and Parkinson\u2019s disease patients (P1-11.007)","volume":"100","author":"Shering","year":"2023","journal-title":"Neurology"},{"issue":"7","key":"10.1016\/j.neurot.2025.e00548_bib52","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/S1474-4422(20)30136-8","article-title":"Safety and immunogenicity of the \u03b1-synuclein active immunotherapeutic PD01A in patients with Parkinson\u2019s disease: a randomised, single-blinded, phase 1 trial","volume":"19","author":"Volc","year":"2020","journal-title":"Lancet Neurol"},{"issue":"9","key":"10.1016\/j.neurot.2025.e00548_bib53","doi-asserted-by":"crossref","first-page":"2631","DOI":"10.1038\/s41591-024-03101-8","article-title":"Target engagement and immunogenicity of an active immunotherapeutic targeting pathological \u03b1-synuclein: a phase 1 placebo-controlled trial","volume":"30","author":"Eijsvogel","year":"2024","journal-title":"Nat Med"},{"issue":"5","key":"10.1016\/j.neurot.2025.e00548_bib54","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1056\/NEJMoa2202867","article-title":"Trial of Prasinezumab in early-stage Parkinson\u2019s disease","volume":"387","author":"Pagano","year":"2022","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1016\/j.neurot.2025.e00548_bib56","doi-asserted-by":"crossref","DOI":"10.1080\/19420862.2023.2261509","article-title":"Delivery of the BrainshuttleTM amyloid-beta antibody fusion trontinemab to non-human primate brain and projected efficacious dose regimens in humans","volume":"15","author":"Grimm","year":"2023","journal-title":"mAbs"},{"issue":"754","key":"10.1016\/j.neurot.2025.e00548_bib57","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.adj5958","article-title":"Nasal tau immunotherapy clears intracellular tau pathology and improves cognitive functions in aged tauopathy mice","volume":"16","author":"Gaikwad","year":"2024","journal-title":"Sci Transl Med"},{"issue":"15","key":"10.1016\/j.neurot.2025.e00548_bib58","doi-asserted-by":"crossref","first-page":"8554","DOI":"10.1073\/pnas.141230798","article-title":"Protacs: chimeric molecules that target proteins to the Skp1-Cullin-F box complex for ubiquitination and degradation","volume":"98","author":"Sakamoto","year":"2001","journal-title":"Proc Natl Acad Sci USA"},{"issue":"5","key":"10.1016\/j.neurot.2025.e00548_bib59","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1002\/(SICI)1521-1878(200005)22:5<442::AID-BIES6>3.0.CO;2-Q","article-title":"Ubiquitin-mediated proteolysis: biological regulation via destruction","volume":"22","author":"Ciechanover","year":"2000","journal-title":"Bioessays"},{"issue":"18","key":"10.1016\/j.neurot.2025.e00548_bib60","doi-asserted-by":"crossref","DOI":"10.3390\/ijms231810328","article-title":"Recent advances in PROTACs for drug targeted protein research","volume":"23","author":"Yao","year":"2022","journal-title":"Int J Mol Sci"},{"issue":"22","key":"10.1016\/j.neurot.2025.e00548_bib61","doi-asserted-by":"crossref","first-page":"5904","DOI":"10.1016\/j.bmcl.2008.07.114","article-title":"Targeted intracellular protein degradation induced by a small molecule: en route to chemical proteomics","volume":"18","author":"Schneekloth","year":"2008","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.neurot.2025.e00548_bib62","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.ejmech.2018.01.063","article-title":"Discovery of a Keap1-dependent peptide PROTAC to knockdown Tau by ubiquitination-proteasome degradation pathway","volume":"146","author":"Lu","year":"2018","journal-title":"Eur J Med Chem"},{"issue":"11","key":"10.1016\/j.neurot.2025.e00548_bib63","doi-asserted-by":"crossref","first-page":"5279","DOI":"10.7150\/thno.55680","article-title":"A\u00a0novel small-molecule PROTAC selectively promotes tau clearance to improve cognitive functions in Alzheimer-like models","volume":"11","author":"Wang","year":"2021","journal-title":"Theranostics"},{"key":"10.1016\/j.neurot.2025.e00548_bib64","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.45457","article-title":"Targeted degradation of aberrant tau in frontotemporal dementia patient-derived neuronal cell models","volume":"8","author":"Silva","year":"2019","journal-title":"Elife"},{"issue":"6","key":"10.1016\/j.neurot.2025.e00548_bib65","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1021\/acsmedchemlett.0c00192","article-title":"PROTAC compounds targeting \u03b1-synuclein protein for treating neurogenerative disorders: Alzheimer\u2019s and Parkinson\u2019s diseases","volume":"11","author":"Kargbo","year":"2020","journal-title":"ACS Med Chem Lett"},{"issue":"5","key":"10.1016\/j.neurot.2025.e00548_bib66","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.3390\/pharmaceutics15051467","article-title":"Synthesis and preliminary characterization of putative Anle138b-centered PROTACs against \u03b1-synuclein aggregation","volume":"15","author":"Pedrini","year":"2023","journal-title":"Pharmaceutics"},{"issue":"11","key":"10.1016\/j.neurot.2025.e00548_bib67","doi-asserted-by":"crossref","first-page":"4458","DOI":"10.3390\/molecules28114458","article-title":"Design, synthesis and biological evaluation of \u03b1-synuclein proteolysis-targeting chimeras","volume":"28","author":"Wen","year":"2023","journal-title":"Molecules"},{"issue":"12","key":"10.1016\/j.neurot.2025.e00548_bib68","doi-asserted-by":"crossref","first-page":"7926","DOI":"10.1021\/acs.jmedchem.3c00274","article-title":"Discovery of small-molecule degraders for alpha-synuclein aggregates","volume":"66","author":"Tong","year":"2023","journal-title":"J\u00a0Med Chem"},{"issue":"5","key":"10.1016\/j.neurot.2025.e00548_bib69","doi-asserted-by":"crossref","first-page":"3448","DOI":"10.1021\/acs.jmedchem.3c01719","article-title":"Discovery of effective dual PROTAC degraders for neurodegenerative disease-associated aggregates","volume":"67","author":"Zhu","year":"2024","journal-title":"J\u00a0Med Chem"},{"issue":"21","key":"10.1016\/j.neurot.2025.e00548_bib70","doi-asserted-by":"crossref","first-page":"5967","DOI":"10.1016\/j.cell.2024.08.024","article-title":"Co-opting templated aggregation to degrade pathogenic tau assemblies and improve motor function","volume":"187","author":"Miller","year":"2024","journal-title":"Cell"},{"key":"10.1016\/j.neurot.2025.e00548_bib71","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1039\/c39890000816","article-title":"Protonated pteridine and flavin analogues acting as efficient and substrate-selective photocatalysts in the oxidation of benzyl alcohol derivatives by oxygen","author":"Fukuzumi","year":"1989","journal-title":"J\u00a0Chem Soc, Chem Commun"},{"issue":"5","key":"10.1016\/j.neurot.2025.e00548_bib72","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1002\/cctc.201100372","article-title":"Photooxidation of sulfides to sulfoxides mediated by tetra-O-acetylriboflavin and visible light","volume":"4","author":"Dad\u2019ov\u00e1","year":"2012","journal-title":"ChemCatChem"},{"key":"10.1016\/j.neurot.2025.e00548_bib73","doi-asserted-by":"crossref","first-page":"11519","DOI":"10.1021\/jp207118x","article-title":"Interaction of thioflavin T with amyloid fibrils: stoichiometry and affinity of dye binding, absorption spectra of bound dye","volume":"115","author":"Sulatskaya","year":"2011","journal-title":"J\u00a0Phys Chem B"},{"issue":"8","key":"10.1016\/j.neurot.2025.e00548_bib74","doi-asserted-by":"crossref","first-page":"2538","DOI":"10.1021\/jp2083055","article-title":"Interaction of thioflavin T with amyloid fibrils: fluorescence quantum yield of bound dye","volume":"116","author":"Sulatskaya","year":"2012","journal-title":"J\u00a0Phys Chem B"},{"issue":"5","key":"10.1016\/j.neurot.2025.e00548_bib75","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1038\/nn.3697","article-title":"Single App knock-in mouse models of Alzheimer\u2019s disease","volume":"17","author":"Saito","year":"2014","journal-title":"Nat Neurosci"},{"issue":"11","key":"10.1016\/j.neurot.2025.e00548_bib76","doi-asserted-by":"crossref","first-page":"10148","DOI":"10.1021\/acsomega.2c07468","article-title":"Partial destabilization of amyloid-\u03b2 protofibril by methionine photo-oxidation: a molecular dynamic simulation study","volume":"8","author":"Maghsoodi","year":"2023","journal-title":"ACS Omega"},{"issue":"5","key":"10.1016\/j.neurot.2025.e00548_bib77","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.1021\/ja108943n","article-title":"Protonation, tautomerization, and rotameric structure of histidine: a comprehensive study by magic-angle-spinning solid-state NMR","volume":"133","author":"Li","year":"2011","journal-title":"J\u00a0Am Chem Soc"},{"issue":"10","key":"10.1016\/j.neurot.2025.e00548_bib78","doi-asserted-by":"crossref","first-page":"4940","DOI":"10.1021\/ac500334k","article-title":"Discovery and characterization of a photo-oxidative histidine-histidine cross-link in IgG1 antibody utilizing 18O-labeling and mass spectrometry","volume":"86","author":"Liu","year":"2014","journal-title":"Anal Chem"},{"issue":"15","key":"10.1016\/j.neurot.2025.e00548_bib79","doi-asserted-by":"crossref","first-page":"7915","DOI":"10.1021\/acs.analchem.7b00860","article-title":"Discovery and characterization of histidine oxidation initiated cross-links in an IgG1 monoclonal antibody","volume":"89","author":"Xu","year":"2017","journal-title":"Anal Chem."},{"issue":"20","key":"10.1016\/j.neurot.2025.e00548_bib80","doi-asserted-by":"crossref","first-page":"7726","DOI":"10.1021\/jacs.1c01626","article-title":"Proximity histidine labeling by umpolung strategy using singlet oxygen","volume":"143","author":"Nakane","year":"2021","journal-title":"J\u00a0Am Chem Soc"},{"issue":"22","key":"10.1016\/j.neurot.2025.e00548_bib81","doi-asserted-by":"crossref","first-page":"6546","DOI":"10.1002\/anie.201803013","article-title":"A\u00a0highly efficient near-infrared-emissive copolymer with a N=N double-bond \u03c0-conjugated system based on a fused azobenzene-boron complex","volume":"57","author":"Gon","year":"2018","journal-title":"Angew Chem Int Ed"},{"issue":"32","key":"10.1016\/j.neurot.2025.e00548_bib82","doi-asserted-by":"crossref","first-page":"41843","DOI":"10.1021\/acsami.4c06901","article-title":"Chemiexcitation-triggered photosensitizer activation for photooxidation of A\u03b21-42 aggregates","volume":"16","author":"Liu","year":"2024","journal-title":"ACS Appl Mater Interfaces"},{"issue":"45","key":"10.1016\/j.neurot.2025.e00548_bib83","doi-asserted-by":"crossref","DOI":"10.1002\/anie.202312519","article-title":"A\u00a0photolabile curcumin-diazirine analogue enables phototherapy with physically and molecularly produced light for Alzheimer\u2019s disease treatment","volume":"62","author":"Kuang","year":"2023","journal-title":"Angew Chem Int Ed"},{"key":"10.1016\/j.neurot.2025.e00548_bib84","doi-asserted-by":"crossref","DOI":"10.1016\/j.nbd.2023.106050","article-title":"Immunotherapy targeting the C-terminal domain of TDP-43 decreases neuropathology and confers neuroprotection in mouse models of ALS\/FTD","volume":"179","author":"Afroz","year":"2023","journal-title":"Neurobiol Dis"},{"key":"10.1016\/j.neurot.2025.e00548_bib85","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1186\/s40478-023-01592-z","article-title":"Targeting the glycine-rich domain of TDP-43 with antibodies prevents its aggregation in vitro and reduces neurofilament levels in vivo","volume":"11","author":"Riemenschneider","year":"2023","journal-title":"Acta Neuropathol Commun"},{"key":"10.1016\/j.neurot.2025.e00548_bib86","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/s12929-023-00921-7","article-title":"Degradation of neurodegenerative disease-associated TDP-43 aggregates and oligomers via a proteolysis-targeting chimera","volume":"30","author":"Tseng","year":"2023","journal-title":"J\u00a0Biomed Sci"},{"issue":"3","key":"10.1016\/j.neurot.2025.e00548_bib87","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1056\/NEJMoa2303765","article-title":"Phase 1 trial of antibody NI006 for depletion of cardiac transthyretin amyloid","volume":"389","author":"Garcia-Pavia","year":"2023","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"10.1016\/j.neurot.2025.e00548_bib88","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1016\/S0002-9440(10)64639-1","article-title":"Antibody-mediated resolution of light chain-associated amyloid deposits","volume":"157","author":"Hrncic","year":"2000","journal-title":"Am J Pathol"},{"issue":"sup1","key":"10.1016\/j.neurot.2025.e00548_bib89","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1080\/13506129.2017.1292900","article-title":"Interim analysis of the phase 1a\/b study of chimeric fibril-reactive monoclonal\u00a0antibody 11-1F4 in patients with AL amyloidosis","volume":"24","author":"Edwards","year":"2017","journal-title":"Amyloid"},{"issue":"sup1","key":"10.1016\/j.neurot.2025.e00548_bib90","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1080\/13506129.2019.1584892","article-title":"One year follow up analysis of the phase 1a\/b study of chimeric fibril-reactive monoclonal antibody 11-1F4 in patients with AL amyloidosis","volume":"26","author":"Edwards","year":"2019","journal-title":"Amyloid"}],"container-title":["Neurotherapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747925000261?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747925000261?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T07:46:28Z","timestamp":1778831188000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1878747925000261"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":89,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["S1878747925000261"],"URL":"https:\/\/doi.org\/10.1016\/j.neurot.2025.e00548","relation":{},"ISSN":["1878-7479"],"issn-type":[{"value":"1878-7479","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Proteolytic therapeutic modalities for amyloidoses: Insights into immunotherapy, PROTAC, and photo-oxygenation","name":"articletitle","label":"Article Title"},{"value":"Neurotherapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neurot.2025.e00548","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Inc. on behalf of American Society for Experimental NeuroTherapeutics.","name":"copyright","label":"Copyright"}],"article-number":"e00548"}}